VEGFR-2 Protein, Mouse (HEK293, mFc)

VEGFR-2 protein is an important tyrosine protein kinase receptor. As a cell surface receptor for VEGFA, VEGFC and VEGFD, it plays an important role in the regulation of angiogenesis, vascular development, permeability and embryonic hematopoiesis. It actively promotes endothelial cell proliferation, survival, migration, differentiation, and actin cytoskeletal reorganization. VEGFR-2 Protein, Mouse (HEK293, mFc) is the recombinant mouse-derived VEGFR-2 protein, expressed by HEK293, with C-mFc labeled tag.

For research use only. We do not sell to patients.
  • Species: Mouse
  • Source: HEK293
  • Storage:
    Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
  • Biological Activity
  • Technical Parameters
  • Product Properties
  • Documentation
  • Help & FAQs

Biological Activity

Description

VEGFR-2 protein is an important tyrosine protein kinase receptor. As a cell surface receptor for VEGFA, VEGFC and VEGFD, it plays an important role in the regulation of angiogenesis, vascular development, permeability and embryonic hematopoiesis. It actively promotes endothelial cell proliferation, survival, migration, differentiation, and actin cytoskeletal reorganization. VEGFR-2 Protein, Mouse (HEK293, mFc) is the recombinant mouse-derived VEGFR-2 protein, expressed by HEK293, with C-mFc labeled tag.

Background

VEGFR-2, a tyrosine-protein kinase, serves as a crucial cell-surface receptor for VEGFA, VEGFC, and VEGFD, playing a fundamental role in angiogenesis regulation, vascular development, permeability, and embryonic hematopoiesis. It actively promotes endothelial cell proliferation, survival, migration, and differentiation, as well as the reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, like isoform 2, may function as decoy receptors, particularly in negatively regulating VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the availability of free VEGFA and/or VEGFC and preventing their binding to FLT4. VEGFR-2 modulates FLT1 and FLT4 signaling through heterodimer formation. The binding of vascular growth factors to isoform 1 initiates various signaling cascades, including the activation of PLCG1, resulting in the production of diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Additionally, it mediates the activation of MAPK1/ERK2, MAPK3/ERK1, AKT1, and the phosphorylation of PIK3R1, contributing to phosphatidylinositol 3-kinase regulation and actin cytoskeleton reorganization. VEGFR-2 is indispensable for VEGFA-induced NOS2 and NOS3 expression, leading to nitric oxide production by endothelial cells, and it phosphorylates PLCG1, FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1, and SRC.

Technical Parameters

  • Species Mouse
  • Source HEK293
  • Tag C-mFc
  • Accession
  • Gene ID
  • Molecular Construction
    • N-term
    • VEGFR-2 (A20-E762)
      Accession # P35918
    • mFc
    • C-term
  • Protein Length

    Extracellular Domain

  • Synonyms

    KDR; Fetal Liver Kinase 1; Kinase Insert Domain Receptor; Vascular Endothelial Growth Factor Receptor 2 Variant; Vascular Endothelial Growth Factor Receptor 2; Tyrosine Kinase Growth Factor Receptor; VEGFR2; Receptor Protein-Tyrosine Kinase; FLK1; Fetal L

  • AA Sequence

    ASVGLPGDFLHPPKLSTQKDILTILANTTLQITCRGQRDLDWLWPNAQRDSEERVLVTECGGGDSIFCKTLTIPRVVGNDTGAYKCSYRDVDIASTVYVYVRDYRSPFIASVSDQHGIVYITENKNKTVVIPCRGSISNLNVSLCARYPEKRFVPDGNRISWDSEIGFTLPSYMISYAGMVFCEAKINDETYQSIMYIVVVVGYRIYDVILSPPHEIELSAGEKLVLNCTARTELNVGLDFTWHSPPSKSHHKKIVNRDVKPFPGTVAKMFLSTLTIESVTKSDQGEYTCVASSGRMIKRNRTFVRVHTKPFIAFGSGMKSLVEATVGSQVRIPVKYLSYPAPDIKWYRNGRPIESNYTMIVGDELTIMEVTERDAGNYTVILTNPISMEKQSHMVSLVVNVPPQIGEKALISPMDSYQYGTMQTLTCTVYANPPLHHIQWYWQLEEACSYRPGQTSPYACKEWRHVEDFQGGNKIEVTKNQYALIEGKNKTVSTLVIQAANVSALYKCEAINKAGRGERVISFHVIRGPEITVQPAAQPTEQESVSLLCTADRNTFENLTWYKLGSQATSVHMGESLTPVCKNLDALWKLNGTMFSNSTNDILIVAFQNASLQDQGDYVCSAQDKKTKKRHCLVKQLIILERMAPMITGNLENQTTTIGETIEVTCPASGNPTPHITWFKDNETLVEDSGIVLRDGNRNLTIRRVRKEDGGLYTCQACNVLGCARAETLFIIEGAQEKTNLE

  • Predicted Molecular Mass

    110.1 kDa

  • Molecular Weight

    Approximately 120-135 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.

  • Glycosylation

    Yes

  • Structure/Form

    Monomer

  • Purity

    ≥ 95%, as determined by reducing SDS-PAGE.

Product Properties

Appearance

Lyophilized powder.

Endotoxin Level

<1 EU/μg, determined by LAL method.

Reconstitution

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Storage & Stability

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping

Room temperature in continental US; may vary elsewhere.

Calculators

Reconstitution Calculator

Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration

Volume (to add to vial) Volume (to add to vial)
=
Mass (in vial) Mass (in vial)
÷
Desired Reconstitution Concentration Desired Reconstitution Concentration
Dilution Calculator

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

Concentration (start) Concentration (start)
×
Volume (start) Volume (start)
=
Concentration (final) Concentration (final)
×
Volume (final) Volume (final)
The Specific Activity Calculator Equation
  • Specific Activity (Unit/mg)
  • Biological Activity (ED50)

Specific Activity (Unit/mg) = 106 ÷ Biological Activity (ED50)

Specific Activity (Unit/mg) Specific Activity (Unit/mg)
Unit/mg
= 106 ÷
Biological Activity (ED50) Biological Activity (ED50)
106 ÷
ng/mL
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00